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designed to assess the zinc status in critical care patients with systemic inflammatory response syndrome (SIRS),
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nutritional parameters, plasma and blood cell zinc concentrations, and levels of transcripts for zinc transporters in
whole blood were taken at admission and at the seventh day of the ICU stay. Results: Zinc levels on critical ill patient
are diminish comparing with the healthy control (HS: 0.94   0.19; CIPF: 0.67   0.16 mg/dL). The 58 percent of critical
ill patients showed Zinc plasma deficiency at beginning of study while 50.0 percent of critical ill after 7 days of ICU
stay. ZnT7, ZIP4 and ZIP9 were the zinc transporters with highest expression in whole blood. In general, all Zinc
transporters were significantly down-regulated (P < 0.05) in the critical ill population at admission in comparison with
healthy subjects. Severity scores and inflammation were significantly associated (P < 0.05) with zinc plasma levels,
and zin transporters ZIP3, ZIP4, ZIP8, ZnT6, Znt7. Expression of 11 out of 24 zinc transporters was analysed, and
ZnT1, ZnT4, ZnT5 and ZIP4, which were downregulated by more than 3-fold in whole blood of patients. Conclusion: In
summary, in our study an alteration of zinc status was related with the severity-of-illness scores and inflammation in
critical ill patients since admission in ICU stay. SIRS caused a general shut-down of expression of zinc transporters in
whole blood. That behavior was associated with severity and inflammation of patients at ICU admission regardless
zinc status. We conclude that zinc transporters in blood might be useful indicators of severity of systemic inflammation
and outcome for critically ill patients.
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54 Abstract
55 Introduction: Critically ill patients develop severe stress, inflammation and a clinical 
56 state that may raise the utilization and metabolic replacement of many nutrients and 
57 especially zinc, depleting their body reserves. This study was designed to assess the zinc 
58 status in critical care patients with systemic inflammatory response syndrome (SIRS), 
59 comparing them with a group of healthy people, and studying the association with 
60 expression of zinc transporters. 
61 Material and methods: This investigation was a prospective, multicentre, comparative, 
62 observational and analytic study. Twelve critically ill patients from different hospitals 
63 and 12 healthy subjects from Granada, Spain, all with informed consent were recruited. 
64 Data on daily nutritional assessment, ICU severity scores, inflammation, clinical and 
65 nutritional parameters, plasma and blood cell zinc concentrations, and levels of 
66 transcripts for zinc transporters in whole blood were taken at admission and at the 
67 seventh day of the ICU stay.
68 Results: Zinc levels on critical ill patient are diminish comparing with the healthy 
69 control (HS: 0.94 ± 0.19; CIPF: 0.67 ± 0.16 mg/dL). The 58 percent of critical ill 
70 patients showed Zinc plasma deficiency at beginning of study while 50.0 percent of 
71 critical ill after 7 days of ICU stay. ZnT7, ZIP4 and ZIP9 were the zinc transporters with 
72 highest expression in whole blood. In general, all Zinc transporters were significantly 
73 down-regulated (P < 0.05) in the critical ill population at admission in comparison with 
74 healthy subjects. Severity scores and inflammation were significantly associated (P < 
75 0.05) with zinc plasma levels, and zin transporters ZIP3, ZIP4, ZIP8, ZnT6, Znt7. 
76 Expression of 11 out of 24 zinc transporters was analysed, and ZnT1, ZnT4, ZnT5 and 
77 ZIP4, which were downregulated by more than 3-fold in whole blood of patients. 
78 Conclusion: In summary, in our study an alteration of zinc status was related with the 
79 severity-of-illness scores and inflammation in critical ill patients since admission in ICU 
80 stay. SIRS caused a general shut-down of expression of zinc transporters in whole 
81 blood. That behavior was associated with severity and inflammation of patients at ICU 
82 admission regardless zinc status. We conclude that zinc transporters in blood might be 
83 useful indicators of severity of systemic inflammation and outcome for critically ill 
84 patients.
85
86 Keywords
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88 Zinc transporters; Severity.
89
90 Highlights
91 Critical ill patients are deficient in plasma and cellular zinc.
92 Down-regulation of zinc transporters linked to critical illness.
93 New zinc transporters as biomarker candidates for severity and inflammation in critical 
94 ill patients.
95
96 Introduction
97 Zinc is an essential component in all levels of metabolism, and is a key component in 
98 structure of genetic material [1]. Zinc homeostasis depends on the balance between 
99 absorption of zinc from diet and endogenous secretions by the daily intake of the 
100 element [2]. These basic conditions may be complicated by diseases or dysfunctions as 
101 multiple organ failure that in critically ill patients require a correct and timely provision 
102 of energy and nutrients as zinc that can save life, so adequate nutrition should be 
103 included in their clinical treatment [3, 4]. In critically ill patients, low zinc 
104 concentrations have been reported linked to oxidative stress, systemic inflammatory 
105 response syndrome (SIRS) and immune disorders [4, 5], particularly in patients with 
106 sepsis [6-9]. Then, zinc deficiency could be considered as an important factor in the 
107 pathogenesis of different diseases [5]. Nevertheless, increased zinc demands are 
108 justified by hypercatabolic situation and a high degree of stress as surgical, traumatic 
109 and septic shock, which could develop malnutrition status [10].
110 Zinc is an element very difficult to be determined by non-invasive techniques in human 
111 body tissues, therefore its represents a challenge in the determination of a suitable 
112 biomarker of zinc status for critical condition. Although studies concluded that plasma, 
113 urinary and hair zinc are reliable biomarkers of zinc status [11], there is no consensus. 
114 Recently, Lowe et. al. [12], concluded that zinc is mostly determined in plasma or 
115 serum samples. Nevertheless, peripheral blood tissue is an accessible tissue to use for 
116 the exploration of biomarkers for human zinc homeostasis [13] but cellular blood zinc 
117 needs further investigation [12]. Over the time has been studied to find other biomarkers 
118 for zinc status in human body [11] on these days many of research is concentrated on 
119 zinc transporters. Some authors suggest that zinc transporters could express 
120 independently of dietary or plasma zinc in healthy individuals [14]. On the other hand, 
121 the dysregulation of expression and activity of ZIP and ZnT transporters involved in the 
122 pathogenesis and progression in chronic diseases have been described [15]. However, 
123 their molecular relationship with the etiology of acute diseases is far from complete. 
124 Clarifying these issues would lead to therapeutic innovation in critical illness, and 
125 therefore, great attention should be paid to ZIP and ZnT transporters.
126 There are no previous studies that were comprehensively addressed the zinc transporters 
127 levels in the cell membrane in humans. Our aim was to investigate the zinc 
128 concentrations and its association with the expression level of all zinc transporters in 
129 blood from healthy and critically ill individuals and determine their differences in 
130 expression. We also want to explore the relationship among zinc expression transporter 
131 levels in blood and the severity situation in critical ill condition. It is indispensable to 
132 find a biomarker for zinc status in order to ameliorate the evolution of critical ill patient 
133 and to optimize their clinical intervention during their ICU stay.
134
135 Material and methods
136 Study design
137 The study design is based on a prospective, multicentre, observational and analytic 
138 study, monitoring the critically ill patient, from admission until the seventh day of ICU 
139 stay, from different hospitals of Southern Spain (Virgen de las Nieves, San Cecilio, 
140 General of Baza and Santa Ana of Motril, Granada). The study was carried out 
141 according to the code of ethics of the World Medical Association (Declaration of 
142 Helsinki) for experiments involving humans and the International Conference on 
143 Harmonization/Good Clinical Practice Standards. Informed consent was obtained from 
144 patients or family who had agreed to participate in the study, considering the approval 
145 of the Ethics Committee and the Research Committee of the Centre involved.
146 Participants
147 A total of 12 and 12 subjects were included in healthy control (HS) and critically ill 
148 groups, respectively (CIPB, critical ill patients on admission; CIPF critical ill patient 
149 follow-up), aged and gender matched. Inclusion criteria for the healthy population were: 
150 not to present any alteration that could have influence on their nutritional status and to 
151 have agreed to form part of the study. In critical ill population, the study was carried out 
152 with consecutive patients admitted to ICU. The criteria to be included in the study were: 
153 critically ill patients older than 18 years, admitted in the ICU; with SIRS and APACHE 
154 II score >15; to have artificial nutritional support (enteral and mixed enteral and 
155 parenteral nutrition); to present no neurological, muscular, skeletal, or situations that 
156 affected the mouth or upper digestive tract or contraindicate the passage of nutrients to 
157 the other portions of the digestive system; and to continue in the Unit for at least 7 days. 
158 Exclusion criteria were: refusal by the patient or their legal representatives to participate 
159 in the study; pregnancy; highly contagious disease; allergies; cancer; HIV; food orally 
160 intake before obtaining the analytical sample at baseline; intolerance or contraindication 
161 for using enteral route. Clinical characteristics as age, sex and diagnosis were recorded 
162 at study enrolment (ICU admission). SIRS, the Acute Physiology and Chronic Health 
163 Evaluation (APACHE II) and the Sequential Organ Failure Assessment (SOFA) scores 
164 and mortality was included at admission and seven days in ICU stay.
165 Nutritional profile
166 Nutritional intake profile in healthy population was made through personal interview by 
167 trained staff in the use of nutritional techniques, employing questionnaires with the 
168 following sections: personal data and consumption habits, the nutritional intake by 72 h 
169 recall and food frequency consumption (FFQ) questionnaires. Nutrient intake and 
170 adequacy were calculated with the Nutriber® software, comparing with the 
171 Recommended Dietary Allowances (RDAs) for healthy population [16]. Nutritional 
172 support protocol in critical ill patients was assessed according to the Clinical Nutrition 
173 Units of hospitals, based on American Society for Parenteral and Enteral Nutrition and 
174 the European Society of Parenteral and Enteral Nutrition Guidelines [17]. All patients 
175 received nutritional standard support via enteral, parenteral or combined, administrating 
176 nutritional formulas elaborated in the pharmacies of the hospitals or from commercial 
177 products. A daily nutritional log was kept for each patient (type, volume and 
178 composition of intake, tolerance, among other factors) from admission to seven days in 
179 ICU. Zinc support was daily calculated and registered by the nutritionists and 
180 represented as the average of a seven-day period of stay the ICU.
181 Biochemical parameters
182 Fasting blood samples (10 mL) were drawn from ICU patients (between the hours of 
183 08:30 am and 10:00 am during fasting) by venepuncture after the hemodynamic 
184 stabilization phase of admission and after 7 days of stay. The same methodology was 
185 applied for healthy subjects for biochemical testing. Vacutainer tubes (Venoject®, BD, 
186 UK) containing a solution of heparin of lithium as anticoagulant were used. Samples 
187 were centrifuged at 3000 RPM for 15 minutes at 4°C. Blood drawn was centrifuged to 
188 separate plasma and cells and stored at -80 °C. Biochemical variables such as glucose, 
189 albumin, prealbumin, urea, uric acid, alkaline phosphatase, CPK, C-reactive protein 
190 (CRP), rheumatoid factor, total protein, transferrin, homocysteine, leucocytes, cooper 
191 and iron concentrations were determined by the hospital laboratory using standard 
192 techniques and following the quality control and established procedures.
193 Plasma and cellular zinc
194 Plasma and cellular zinc was determined in wet-mineralized triplicate samples [18, 19]. 
195 Inductively couple plasma mass spectrometer (ICP, Agilent, UK) was selected for 
196 plasma zinc analysis. All the variables were taken at day 0 and day 7 calculating for 
197 each variable the mean difference assuming a maximum error of 5% and a confidence 
198 level of 95%.
199 Gene expression 
200 RNA isolation
201 Blood and RNA Preparation 2.5 ml of human peripheral blood was stored in 
202 PAXgene™ whole-blood RNA tubes (Preanalytix) and separated following standard 
203 methodology (Qiagen) before storage at -80ºC. Total RNA was extracted and purified 
204 using PAXgene™ Blood RNA Kit (Qiagen). 1 μg of total RNA was reverse transcribed 
205 to generate complementary DNA by ThermoScript RNase H-Reverse Transcriptase 
206 (Invitrogen Life Technologies, Carlsbad, CA) followed by dilution (1:10) with RNase-
207 free water. The complementary DNA was subjected to quantitative polymerase chain 
208 reaction (PCR) analysis by using SYBR Green PCR Master Mix and a HT7900 
209 sequence detection system (Applied Biosystems). ∆Ct values were used for all statistical 
210 analyses and then transformed to a relative copy number (RCN) value to facilitate the 
211 ease of data interpretation. The RCN of selected genes were determined by 
212 normalization to the expression of the 3 housekeeping genes: Glyceraldehyde 3-
213 Phosphate Dehydrogenase (GAPDH), Tyrosine 3-monooxygenase/tryptophan 5-
214 monooxygenase activation protein (YWHAZ) and Ubiquitin C (UBC). RCN = E-∆Ct x 
215 100 where E denotes the efficiency of the PCR, and ∆Ct denotes the Ct target minus the 
216 Ct reference (the average of 3 housekeeping genes). PCR primer pairs, including those 
217 for all known human zinc transporters, were previously validated and reported [7]. Zinc 
218 transporters with ΔCT > 13 were considered there are not expressed, or the expression 
219 is too low to be detected and were not included in the statistical analysis.
220 Statistical analysis
221 Statistical analysis was performed with version 17.0 of the Statistical Package for Social 
222 Sciences (SPSS, Chicago, IL, USA). Descriptive statistics were computed for the 
223 characteristics of the study population and the biomechanical parameters. Data were 
224 expressed as means and standard deviation (SD). For continuous variables, the 
225 assumption of normality was tested using the Shapiro Wilk curve-fitting test. The 
226 differences between HS and CIP groups were evaluated by using the normal 
227 standardized range using Student’s t test. The paired t-test was used to compare the 
228 evolution of the critical patient in ICU. Bivariate correlation was used to evaluate 
229 plasma and cellular zinc concentrations and severity scores with the expression of zinc 
230 transporters using the Pearson correlation coefficient. The severity and inflammation 
231 variables were dichotomized by the median in order to study their influence on the 
232 plasma and cellular zinc status, the zinc-albumin ratio, and the expression of the zinc 
233 transporters. The differences between the groups for these parameters were compared 
234 using the paired t-test. Data are presented as box-and-whisker plots showing median, 
235 interquartile, and full range or individual data points. The level of significance was set 
236 at 0.05.
237
238 Results
239 Table 1 summarizes the study population characteristics, the severity scores and the 
240 diagnosis of the critical population in the ICU. The critical care population showed no 
241 significant differences in comparison to the healthy subject control population in 
242 energy, macronutrient and socio-demographic variables studied. The most frequent 
243 diseases presented by the patients on ICU admission were respiratory (33.4 percent), 
244 cardiovascular (33.3 percent) and abdominal (33.3 percent). APACHE and SOFA 
245 scores showed an improvement thorough the ICU stay being significant for the 
246 APACHE score at 7 days of ICU stay (P = 0.03). About energy and macronutrients 
247 support, our results showed an energy support was below 2/3 of recommendations in 14 
248 percent of healthy controls against the 60% of critical ill. Critical ill patient received 
249 significantly less CHO support than control through the study period (P < 0.01). In 
250 critical ill patients, all patients had artificial nutrition: EN was received by 50% of the 
251 critical care patients, PN by 33 percent and mixed nutrition (EN + PN) by 17 percent of 
252 patients. 
253 Table 2 summarizes the biochemical values of the study population. During the period 
254 studied, clinical parameters were into the reference values for the healthy population. In 
255 contrast, critically ill condition showed significant differences (P < 0.05) in clinical and 
256 nutritional parameters in comparison with the healthy subjects. All parameters in 
257 critically ill patients remained without changes during ICU stay excluding uric acid, 
258 creatinine and CRP (p < 0.05).
259 Fig. 1 shows the zinc status in accordance to zinc supply (Fig. 1A), the plasma zinc 
260 levels (Fig. 1B) and cellular zinc (Fig. 1C) in healthy controls and critically ill patients. 
261 Regarding, zinc supply no significant differences were found between healthy controls 
262 and the critical ill on EN or EN + PN (Fig. 1A). Moreover, there were no patients with 
263 zinc supply below the recommendations on EN when the limit was set in 8 mg per day. 
264 Nevertheless, a total of 50 percent of patients with PN presented an insufficient zinc 
265 supply. In relation to plasma (Fig. 1B) and cellular zinc (Fig. 1C), significant changes 
266 were found between critical ill patients at seven days in ICU stay and healthy controls 
267 (p < 0.05). We analysed the contribution of each compartment to the total amount of 
268 zinc in blood. The healthy controls presented a total of 86.0 percent of the zinc content 
269 in blood cells and 13.2 percent in plasma. The critical ill population presented a 25.2 
270 percent of the zinc in plasma at admission in ICU and 27.3 percent in plasma after 7 
271 days in ICU stay. Moreover, the 58 percent of critical ill patients showed zinc plasma 
272 deficiency at beginning of study while 50.0 percent of critical ill after 7 days of ICU 
273 stay.
274 Fig. 2A represents the heat map showing an overview of the Ct quality categories that 
275 have been assigned to the different groups. In healthy subjects, ZnT7 genes, ZIP1 and 
276 ZIP 9 and ZIP4 showed the highest expression profile. In contrast, low or no expression 
277 was detected for ZnT2, ZnT3, ZnT8, ZnT10, ZIP2 and ZIP12 genes. In the critical ill 
278 patients group (both at admission and at 7 days in ICU stay) low or no expression was 
279 detected of, ZnT2, ZnT3, ZnT4, ZnT8, ZnT10, ZIP2, ZIP5, ZIP6, and ZIP12 genes. 
280 From the futures analysis we had excluded ZnT2, ZnT3, ZnT4, ZnT8, ZnT10, ZIP2 and 
281 ZIP12. For ZnT9, ZIP5, ZIP 6, ZIP11 and ZIP14 the expression is borderline, or the 
282 expression is just in one group and diapering form another group. The relative 
283 expression profile was calculated to compare the healthy subjects with respect to critical 
284 ill patients at admission in ICU (Fig. 2B) and critical ill patients at two time points 
285 measured (Fig. 2C). In general, all zinc transporters were significantly down-regulated 
286 (P < 0.05) in the critical ill population at admission in comparison with healthy subjects. 
287 In contrast, when comparing critical ill patients at admission with 7 days in ICU stay, 
288 ZIP1 was the only one statistically significant (P < 0.01). Expression of 11 out of 24 
289 zinc transporters was analysed, and ZnT1, ZnT4, ZnT5 and ZIP4, which were 
290 downregulated by more than 3-fold in whole blood of patients compared to healthy 
291 controls.
292 Based on the observation that the expression of zinc transporters decreased in 
293 conjunction with a critical condition we evaluated the zinc transporters expression in the 
294 context of severity-of-illness scores and zinc status (Table 3). An increased ZIP1 and 
295 ZnT7 expression was directly correlated (p < 0.05) with the APACHE scores on 
296 admission in ICU. Moreover, ZIP7 and ZIP14, and ZIP10 zinc transporters were 
297 significantly associated (P < 0.05) with SOFA score on admission and thorough ICU 
298 stay, respectively. Finally, an additional evaluation was conducted to analyse the 
299 association regarding zinc status and zinc plasma levels. An indirect relationship 
300 observed (P < 0.05) between the status of zinc in plasma and the ZIP13 and ZIP14 
301 expression during the follow-up study. Finally, the relationship between the status of 
302 zinc in blood was explored. Plasma zinc concentrations were directly correlated (P < 
303 0.05) to cellular zinc content in critically ill on admission in ICU.
304 Because circulating zinc is primarily bound to albumin, and because albumin levels 
305 were significantly decreased in critically ill patients on admission (P = 0.01) and seven 
306 days in ICU stay (P = 0.49) compared to healthy controls, we calculated the ratio of 
307 plasma zinc to albumin. The mean zinc/albumin ratio for critical ill patients was 0.28 ± 
308 0.12 mg/dL on admission and 0.29 ± 0.06 mg/dL at seventh day in ICU stay (Fig. 3). 
309 However, no statistical significant differences were found for critical ill comparison 
310 during the follow up study and inflammation and severity scores.
311 Concerning the relationship between severity and inflammation with the altered clinical 
312 parameters in the critical patient, we decided to study whether presenting a higher level 
313 of inflammation or severity significantly affected the expression of zinc transporters 
314 (Fig. 4). In fact, severity-of-illness scores and inflammation were dichotomized by the 
315 median. Related to the status of zinc, critical ill patients with high severity (P = 0.021) 
316 and inflammation (P = 0.048) presented significantly less zinc in plasma compared to 
317 the less severe patients (Fig. 4A). At the same time, a higher severity and inflammation 
318 resulted in a lower expression patterns of the ZIP3 (P = 0.016), ZnT6 (P = 0.003), ZIP8 
319 (P = 0.037), ZnT7 (P = 0.043) and ZIP4 (P = 0.048) transporters at admission ICU (Fig. 
320 4B, Fig. 4C and Fig. 4D). Finally, Fig. 5 shows the RNA expression of ZIP8 in healthy 
321 controls and critically ill patients on admission and within the follow-up study. Inter-
322 groups comparison showed significantly less ZIP8 expresion in critical ill population (P 
323 = 0.012) and healthy controls.
324
325 Discussion
326 The main finding of the present study showed a relationship between inflammation and 
327 severity with zinc in plasma in critical ill patients through ICU stay. A novelty in our 
328 study was the assessment of the expression profile of all zinc transporters. It is 
329 important to mention that our results showed a diminished expression profile in all zinc 
330 transporters mainly due to the critical ill condition. In fact, the decrease in expression of 
331 certain zinc transporters was found to be associated with severity and inflammation of 
332 patients at ICU admission regardless of plasma and cellular zinc status. Based on these 
333 considerations and the difficulty of assessing nutritional status in severely ill subjects, 
334 the design of our study allowed us to determine the relationship between zinc metabolic 
335 status with inflammation and severity suggesting that the critical condition was 
336 correlated with a decrease in the functionality of zinc transporters.
337 About critical illness, a high risk of morbidity and mortality was observed considering 
338 the hyper-catabolic situation due to the high APACHE II and SOFA scores. With 
339 regards to energy and macronutrients support, the control of nutrition support in 
340 critically ill patient is necessary for the maintenance and recover of organic function 
341 expenses [17]. The methodology to predict resting energy expenditure are questionable 
342 in critically ill patients is still difficult to adjust requirements during ICU stay [20]. 
343 Considering the nutritional supply, our results showed no patients with zinc insufficient 
344 supply by EN and PN (2 patients). In general, we did not find significant differences in 
345 zinc supply between groups (HS vs. CIP) and we could consider zinc supply in critical 
346 ill was adequate. Confirming that, several studies demonstrated that mixed EN and PN 
347 supply does not derive nutrient deficiency in critical ill patients [21, 22].
348 Low plasma zinc has been reported previously in ICU populations [4, 6, 9]. In our study 
349 the majority of blood parameters were more affected in ICU patients with sepsis, both 
350 admission and through the ICU stay compared to healthy controls as previous suggested 
351 [22]. We found that critical ill patients presented low zinc plasma levels during ICU 
352 stay. Whereas we did not find significant differences between the control population 
353 and critical patients at admission, we found that 58 percent of the patients presented 
354 deficiencies of plasma zinc. Also, a significant negative association in zinc plasma 
355 concentrations with the severity of illness was observed in the sepsis cohort based on 
356 SOFA score (Fig. 4A), showing that the most severe patients were those with lower 
357 plasma zinc. These findings suggested that perturbations in zinc metabolism were 
358 enhanced in the setting of severe infection. In addition, zinc concentrations predictably 
359 declined with increased severity of illness scores, which was consistent with a study that 
360 was recently conducted in a critically ill paediatric cohort [23]. Other studies [23, 24] 
361 have also reported that the extent of the decline in plasma zinc concentrations was 
362 associated with increased organ failure and mortality suggesting that the zinc 
363 redistribution may be a compensatory mechanism or an indication of declining function 
364 and worsening outcomes.
365 The exact mechanisms by which the decrease in plasma zinc in critical illness occurs are 
366 not clear. It has been postulated that compartmental redistribution of zinc from the 
367 circulation to tissues as part of the acute phase response, resulting in low plasma 
368 concentrations of zinc, is thought to be mediated in part by inflammation, [23] where 
369 zinc is required for synthesis of acute phase proteins [25]. According to that, in our 
370 study, when dichotomized groups by C-reactive protein, patients with higher C-reactive 
371 protein showed significantly lower plasma zinc levels on admission (Fig. 4A). We also 
372 found a tendency to statistical significance (P = 0.078) between levels of C-reactive 
373 protein and plasma zinc status of critical patients at 7 days of ICU stay once patients 
374 were stabilized and reached greater homogeneity as a group. In this sense, as other 
375 authors recently reported, low zinc concentrations has also been associated with 
376 inflammation of the critical ill patient [9].
377 Albumin is a zinc binding protein which levels were significantly decreased in our 
378 critically ill patients on ICU admission and at seven days of ICU stay compared to 
379 healthy controls. Low plasma zinc could be due, at least in part, to a drop-in albumin 
380 levels. Circulating zinc is primarily albumin bound, and thus zinc concentrations are 
381 dependent to some degree on serum albumin levels [23]. In our study, serum zinc levels 
382 and zinc:albumin ratio of the patients were found to be below the reference ranges on 
383 admission to the ICU. In accordance to Cander et al. [6], similar zinc:albumin ratio was 
384 found for critical illness reference (Fig. 3). On the other hand, we found a direct 
385 relationship between the cellular zinc:albumin ratio and the inflammation (r = 0.757; P 
386 = 0.011) for critical ill patients during the follow-up study. Several authors have 
387 suggested that in plasma, zinc is primarily bound to albumin, but the primary functions 
388 of zinc are carried out at the intracellular level [23]. In this sense, the inflammation 
389 could be responsible for the mobilization of zinc at intracellular level due to the higher 
390 cellular zinc:albumin ratio in critical ill at seventh day in ICU stay.
391 Zinc is vital to many cellular functions, including protein synthesis, signal transduction, 
392 and gene transcription and is necessary to maintain proper immune function. Zinc 
393 transporters comprises the SLC30 and SLC39 family members exhibit tissue-specific 
394 expression and respond differently in human health and diseases [26]. Moreover, 
395 dysregulation of expression and activity of both transporters has been suggested to be 
396 involved in the pathogenesis and progression of several diseases although 
397 comprehensive understanding is far from complete [26]. It is indispensable to find a 
398 biomarker in blood for zinc status to ameliorate the evolution of critical ill patient and to 
399 optimize their clinical intervention through the ICU stay. Once of our main purposes 
400 was to explore the relationship among zinc expression of transporter levels in blood and 
401 the severity of critical ill condition. Have been described previously that the regulation 
402 of zinc transporters like ZIP8 [4] and were mainly influenced by severity and 
403 inflammation, respectively. However, we hypothesized that not only those would be 
404 affected by the critical condition. Based on this, we observed that expression of the two 
405 families of zinc transporters, if expressed at all, was altered in total blood during the 
406 early stages of critical illness or sepsis (at admission) compared to the expression profile 
407 in healthy subjects (Fig. 2). The inter groups comparison (CIPB vs HS) revealed that 
408 most of the zinc transporters were found to be significantly down-regulated in critical ill 
409 patients at the admission in ICU. This could suggest that the critical condition could 
410 favor the decrease on the expression patterns of zinc transporters because of the 
411 inflammation and severity in critical ill patients (Fig. 4).
412 There are many studies about zinc transporters but none to determine all zinc 
413 transporters and level of expression of each one in the blood sample. In our study, the 
414 most expressed zinc transporter in both groups was ZnT7, despite it showed a decline of 
415 expression in critical ill patients. We found a positive correlation between ZnT7 
416 expression and APACHE score at admission in ICU (Table 3). On the other hand, 
417 regarding ZnT6, ZnT7 and ZIP3 transporters, when APACHE variable was 
418 dichotomized, we found significantly lower transporter expression in patients with 
419 higher APACHE (Fig. 4B and Fig. 4C). From ZnT family transporters as ZnT1, ZnT5, 
420 ZnT6 and ZnT9 had previously described in blood [1, 14]. In the case of ZnT7, a 
421 protective role has been shown in reducing oxidative stress, inflammation and cellular 
422 apoptosis [3, 27].This seems to be in agreement with our results since we studied 
423 patients with inflammation possibly caused by oxidative stress. ZnT7 is found in 
424 secretory apparatus are responsible for loading zinc to alkaline phosphatases [28] which 
425 has been found that the enzyme to reduce inflammation through dephosphorylation and 
426 thereby detoxification of endotoxin (lipopolysaccharide), which is an important 
427 mediator of sepsis [29].
428 Regarding ZIP family, we observed in ZIP3, ZIP4 and ZIP8 transporters that, when C-
429 reactive protein variable was dichotomized, significantly diminished transporter 
430 expression in patients with higher C-reactive protein (Fig. 4B and Fig. 4D), probably 
431 due to their relationship with inflammation [30]. In our study, ZIP1 resulted a down-
432 regulated significantly (P = 0.007), decreasing its expression after 7 days of ICU stay. 
433 We also found a positive significant correlation between ZIP1 and APACHE score P < 
434 0.05 at the baseline. In critically ill patients the expression of ZIP8 and ZIP9 was 
435 significantly decreased in comparison with healthy subjects (Fig. 2A). Contrary to 
436 Besecker et al. [4], in our case we found a decrease in the expression of ZIP8 mainly 
437 associated with a greater inflammation at the admission of the ICU stay. This trend is 
438 consistent with the response of other transporters equally analysed in our study. ZIP8 
439 might be a potential biomarker for zinc status [4] but in this study, we suggested adding 
440 other zinc transporters including ZIP1, ZIP3, ZIP4, ZIP9, ZnT6 and ZnT7 due to their 
441 high expression in blood and their relation to critical condition.
442 Finding a biomarker for zinc status is mandatory. There is a current appreciated effort 
443 from the different zinc research groups working together on finding the biological 
444 marker for zinc status. In critical ill disease where the metabolism is disrupted, 
445 biochemical parameters are altered cellular and plasma zinc can lead to zinc deficiency. 
446 Then, optimizing nutrition for these patients should be included on clinical protocols. 
447 The SIRS and APACHE and SOFA high scores presented in our patients, supposed an 
448 acute inflammatory status that developed an alteration in the zinc metabolism associated 
449 with severity.
450 To our knowledge, this study is the first to investigate the zinc concentrations in 
451 conjunction with the expression level of all zinc transporters in blood from healthy and 
452 critically ill individuals and determine their differences in expression. Although our 
453 study is based on a relatively small sample, the results have been able to show a 
454 significant response. However, further studies with a larger sample size are necessary to 
455 strengthen the relationship of the low expression of the zinc transporters linked to the 
456 critical disease, and confirm their usefulness as a sensitive and reliable marker of zinc 
457 status.
458 In summary, in our study an alteration of zinc status was related with the severity-of-
459 illness scores and inflammation in critical ill patients since admission in ICU stay. SIRS 
460 caused a general shut-down of expression of zinc transporters in whole blood. That 
461 behavior was associated with severity and inflammation of patients at ICU admission 
462 regardless zinc status. We conclude that zinc transporters in blood might be useful 
463 indicators of severity of systemic inflammation and outcome for critically ill patients.
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579 Fig. 2 (A) Heat map showing an overview of the Ct quality categories that have been 
580 assigned to the different zinc transporters. The categories correspond to “High 
581 expression level”, “Middle expression level” and “Undetermined” with the colour codes 
582 “Red”, “Green-Blue” and “Black” respectively, in healthy subjects (HS) (n = 12) and 
583 critically ill patients (n = 12) at admission (CIPB) and seven days of ICU stay (CIPF). 
584 (B) RNA expression critical ill patients at baseline in intensive care unit vs healthy 
585 subjects. (C) RNA expression critical ill patients at baseline in intensive care unit vs 
586 critical ill patients at baseline in intensive care unit. ∆Ct = Ct (cycle threshold) target - 
587 Ct reference. Statistically significant differences: * = P<0.05; ** = P<0.01.
588
589 Fig. 3 (A) Evaluation of mean (SD) of albumin, (B) plasma zinc:albumin ratio and (C) 
590 cellular zinc:albumin ratio in healthy subjects (HS) (n = 12) compared with critically ill 
591 patients (n = 12) in intensive care unit at admission (CIPB) and seven days (CIPF). 
592 Box-and-whisker plots show median, interquartile and full range. * Significantly 
593 differences between groups (P<0.05, t-student test comparison).
594
595 Fig. 4 Comparative analysis of zinc status and zinc transporters by severity and 
596 inflammation in critically illness. Severity scores including APACHE and SOFA, and 
597 inflamation parameters like CRP were dicotomized by the median value. (A) Plasma 
598 zinc concentrations according to SOFA score and CRP levels in critically ill patients 
599 during the follow-up study (n = 12). (B) RNA expression of ZIP3 by low APACHE vs 
600 high APACHE and low CRP vs high CRP in critically ill patients on ICU admission. 
601 (C) RNA expression of ZnT6 and ZnT by low APACHE vs high APACHE in critically 
602 ill patients on admission in ICU stay. (D) RNA expression of ZIP4 and ZIP8 by low 
603 CRP vs high CRP in critically ill patients on admission and within the follow-up study. 
604 Box-and-whisker plots show median, interquartile and full range. Box-and-whisker 
605 plots show median, interquartile and full range. ∆Ct = Ct (cycle threshold) target - Ct 
606 reference. * Significantly differences between groups (P <0.05, t-student test 
607 comparison). 
608
609 Fig. 5 RNA expression of ZIP8 in healthy controls  (HS) and critically ill patients on 
610 admission (CIPB) and within the follow-up study (CIPF) (n=12). Box-and-whisker plots 
611 show median, interquartile and full range. ∆Ct = Ct (cycle threshold) target - Ct 
612 reference. * Significantly differences between groups (P < 0.05, t-student test 
613 comparison).





Table 1. Characteristics of the study population1.
Characteristics HS CIP
Age (years) 51 ± 2 56 ± 13
Gender (n male (%) / n female (%)) 6 (50) / 6 (50) 6 (50) / 6 (50)
Respiratory - 33.3
Cardiovascular - 33.3Diagnosis (%) Abdominal/hepatic 
disease - 33.3
ICU Mortality (n ([%)) - 2.00 (17.0)
APACHE II CIPB score (mean ± SD) - 13.4 ± 3.15
APACHE II CIPF score (mean ± SD) 8.62 ± 4.03*
SOFA CIPB score (mean ± SD) - 8.50 ± 3.37
SOFA CIPF score (mean ± SD) 5.62 ± 2.92
Shock septic - 27Infection 
grade % Severe SIRS - 73
Body mass index (kg/m2) 25.5 ± 3.13 27.3 ± 11.40
Energy (kcal/day) 1811.4 ± 365.2 1804.5 ± 1122.7
Protein (mg/day) 74.1 ± 15.6 54.2 ± 36.6
Lipid (mg/day) 71.3 ± 28.2 55.3 ± 29.2
Glucose (mg/day) 162.7 ± 139.8*
Carbohydrates Carbohydrates 
(mg/day)
225.5 ± 57.4 80.4 ± 60.7
Fiber (mg/day) 16.27 ± 4.92 13.4 ± 2.26
1 Values are expressed as mean ± standard deviation. Significant differences t-test 
comparison: * = p-value < 0.05. HS, Healthy subjects; CIP, Critical ill patients; CIPB, 
Critical ill patients at baseline; CIPF, Critical ill patients’ follow-up; APACHE II - Acute 
Physiology and Chronic Health Evaluation; SOFA - Sequential Organ Failure 
Assessment; SIRS - Systemic Inflammatory Response Syndrome.
Table 2. Biochemical values of the study population1.
Characteristics HS CIPB CIPF
Glucose (mg/dL) 93.5 ± 25.2 171.5 ± 118.5a 167.5 ± 37.8
Albumin (g/dL) 4.59 ± 0.21 2.6 ± 0.60a 2.7 ± 0.71
Pre-albumin (mg/dL) 25.3 ± 9.78 11.2 ± 4.85a 19.4 ± 11.5
Urea (mg/dl) 33.5 ± 9.07 68.5 ± 42.2a 59.1 ± 31.5
Uric acid (mg/dl) 4.47 ± 1.11 4.44 ± 3.44 2.06 ± 0.77b
Alkaline phosphatase (U/L) 69.6 ± 19.9 84.7 ± 66.1 127.3 ± 105.2
Creatinine (mg/dl) 0.77 ± 0.17 1.39 ± 1.32 0.77 ± 0.50b
CPK (U/L) 84.5 ± 32.8 978.1 ± 1271.1a 368.1± 514.4
C Reactive Protein (mg/dl) 0.21 ± 0.11 15.1 ± 7.65a 8.33 ± 5.38b
Rheumatoid factor (UI/ml) 6.66 ± 2.46 10.9 ± 4.48a 11.4 ± 7.90
Total protein (g/dl) 7.16 ± 0.47 4.86 ± 0.70 5.28 ± 0.66
Transferrin (mg/dl) 267.7 ± 78.7 136.5 ± 93.1a 133.5 ± 58.2
Leucocyte (10^3microl) 6.20 ± 1.39 14.6 ± 4.65a 11.7 ± 4.51
Copper (Cu) (µg/mL) 83.1 ± 12.7 82.2 ± 29.4 80.6 ± 23.1
Iron (Fe) (µg/mL) 128.8 ± 44.2 31.7 ± 21.9a 40.4 ± 32.6
Homocysteine  (µmol/L) 20.8 ± 16.2 11.2 ± 6.4 9.57 ± 2.82a
1 Values are expressed as mean ± SD. HS, Healthy subjects; CIP, Critical ill patients; 
CIPB, Critical ill patients at baseline; CIPF, Critical ill patients follow-up. Significant 
differences t-test comparison: a = P<0.05, HS vs CIPB; b = P<0.05 CIPB vs CIPF.
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